nach oben

Breast Cancer Research and Treatment

Erschienen in:

10.08.2017 | Preclinical study

HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma

verfasst von: Yanjun Hou, Hiroaki Nitta, Lai Wei, Peter M. Banks, Bryce Portier, Anil V. Parwani, Zaibo Li

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Anti-HER2 neoadjuvant chemotherapy has been widely used in HER2-positive breast cancer patients; however, pathologic complete response (pCR) is achieved in only 40–50% of patients. The aim of this study was to investigate the association of HER2 intratumoral heterogeneity (ITH) with response to anti-HER2 neoadjuvant chemotherapy.

Methods

Assessment of HER2 ITH was performed on whole tissue sections of pre-treatment samples from a cohort of 64 invasive breast carcinoma cases originally considered positive for HER2 and treated with anti-HER2 neoadjuvant chemotherapy. Both HER2 gene signal and protein expression were simultaneously evaluated by means of a single-slide dual assay, designated as a HER2 gene-protein assay (GPA). HER2 GPA was carried out as well on surgical resection tissues from 25 cases with incomplete therapeutic response.

Results

Nineteen of 64 cases (30%) showed HER2 ITH. Significantly more cases with HER2 ITH were found in the incomplete response group (56%, 14/25) than in the pCR group (13%, 5/39). Patients without ITH detectable by GPA had a 76% pCR outcome (34/45), as compared to 26% (5/19) for those with detectable ITH. Multivariate analysis demonstrated HER2 ITH, progesterone receptor positivity, and relatively low HER2/chromosome 17 centromere ratio to be significantly associated with incomplete response.

Conclusions

HER2 ITH analyses conducted with GPA method revealed that HER2 ITH is an independent factor predicting incomplete response to anti-HER2 neoadjuvant chemotherapy.

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMed

Press MF, Pike MC, Chazin VR et al (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960–4970PubMed

Tandon AK, Clark GM, Chamness GC et al (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120–1128CrossRefPubMed

Lal P, Salazar PA, Hudis CA et al (2004) HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121:631–636CrossRefPubMed

Park JW, Neve RM, Szollosi J et al (2008) Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 8:392–401CrossRefPubMed

Ross JS, Slodkowska EA, Symmans WF et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368CrossRefPubMed

Olson EM (2012) Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy. J Clin Oncol 30(14):1712–1714CrossRefPubMed

Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648CrossRefPubMed

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792CrossRefPubMed

10.

Seidman AD, Fornier MN, Esteva FJ et al (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587–2595CrossRefPubMed

11.

Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726CrossRefPubMed

12.

Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMed

13.

Viani GA, Afonso SL, Stefano EJ et al (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153CrossRefPubMedPubMedCentral

14.

Nahta R, Yu D, Hung MC et al (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280CrossRefPubMed

15.

Mukohara T (2011) Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 102:1–8CrossRefPubMed

16.

Lewis JT, Ketterling RP, Halling KC et al (2005) Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 124:273–281CrossRefPubMed

17.

Striebel JM, Bhargava R, Horbinski C et al (2008) The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am J Clin Pathol 129:383–390CrossRefPubMed

18.

Brunelli M, Manfrin E, Martignoni G et al (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131:678–682CrossRefPubMed

19.

Seol H, Lee HJ, Choi Y et al (2012) Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 25:938–948CrossRefPubMed

20.

Bartlett AI, Starcyznski J, Robson T et al (2011) Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 136:266–274CrossRefPubMed

21.

Nitta H, Kelly BD, Padilla M et al (2012) A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol 7:60CrossRefPubMedPubMedCentral

22.

Hirschmann A, Lamb TA, Marchal G et al (2012) Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas. Am J Clin Pathol 138:837–844CrossRefPubMed

23.

Li Z, Dabbs DJ, Cooper KL et al (2015) Dual HER2 gene protein assay: focused study of breast cancers with 2 + immunohistochemical expression. Am J Clin Pathol 143(3):451–458CrossRefPubMed

24.

Hou Y, Nitta H, Li Z (2017) HER2 gene protein assay is useful to determine HER2 status and evaluate HER2 heterogeneity in HER2 equivocal breast cancer. Am J Clin Pathol 147:89–95CrossRefPubMed

25.

Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013CrossRefPubMed

26.

Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422CrossRefPubMed

27.

Hanna WM, Rüschoff J, Bilous M et al (2014) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 27:4–18CrossRefPubMed

28.

Ohlschlegel C, Zahel K, Kradolfer D et al (2011) HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 64:1112–1116CrossRefPubMed

29.

Tubbs RR, Hicks DG, Cook J et al (2007) Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 16:207–210CrossRefPubMed

30.

Allison KH, Dintzis SM, Schmidt RA (2011) Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. Am J Clin Pathol 136:864–871CrossRefPubMed

31.

Chang MC, Malowany JI, Mazurkiewicz J et al (2012) ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases. Mod Pathol 25:683–688CrossRefPubMed

32.

Murthy SS, Sandhya DG, Ahmed F et al (2011) Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center. Indian J Pathol Microbiol 54:532–538CrossRefPubMed

33.

Kurozumi S, Padilla M, Kurosumi M et al (2016) HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat 158(1):99–111CrossRefPubMedPubMedCentral

34.

Nitta H, Kelly BD, Allred C et al (2016) The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 66(6):313–324CrossRefPubMed

35.

Untch M, Fasching PA, Konecny GE et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29(25):3351–3357CrossRefPubMed

36.

Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384CrossRefPubMed

37.

Untch M, Rezai M, Loibl S et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28:2024–2031CrossRefPubMed

38.

Guarneri V, Frassoldati A, Bottini A et al (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 30:1989–1995CrossRefPubMed

39.

Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633–640CrossRefPubMed

40.

Bhargava R, Dabbs DJ, Beriwal S et al (2011) Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol 24:367–374CrossRefPubMed

41.

Sánchez-Muñoz A, Navarro-Perez V, Plata-Fernández Y et al (2015) Proliferation determined by Ki-67 defines different pathologic response to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. Clin Breast Cancer 15:343–347CrossRefPubMed

42.

Lee HJ, Seo AN, Kim EJ et al (2014) HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol 142:755–766CrossRefPubMed

43.

Lee HJ, Kim JY, Park SY et al (2015) Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Am J Clin Pathol 144:570–578CrossRefPubMed

Titel: HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
verfasst von: Yanjun Hou
Hiroaki Nitta
Lai Wei
Peter M. Banks
Bryce Portier
Anil V. Parwani
Zaibo Li
Publikationsdatum: 10.08.2017
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4453-8

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Association between survival time with metastatic breast cancer and aggressive end-of-life care

Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones

Impact of pathologic diagnosis of internal mammary lymph node metastasis in clinical N2b and N3b breast cancer patients

Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial

Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast

Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie